Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants

References

• [AAP] American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn2003Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infectionsPediatrics1121442614654627
   PubMed Web of Science ®Google Scholar
• ArnoldSRWangEELawBJ1999Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV database. Pediatric Investigators Collaborative Network on Infections in CanadaPediatr Infect Dis J18866910530581
   PubMed Web of Science ®Google Scholar
• BeelerJAvan Wyke CoelinghK1989Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion functionJ Virol632941502470922
   PubMed Web of Science ®Google Scholar
• BeyerMBartzHHornerK2004Sustained increases in numbers of pulmonary dendritic cells after respiratory syncytial virus infectionJ Allergy Clin Immunol1131273314713917
   PubMed Web of Science ®Google Scholar
• BuckinghamSCJafriHSBushAJ2002A randomized, double-blind, placebo-controlled trial of dexamethasone in severe respiratory syncytial virus (RSV) infection: effects on RSV quantity and clinical outcomeJ Infect Dis1851222812001038
   PubMed Web of Science ®Google Scholar
• Carbonell-EstranyXLGHultquistMConnorEthe Motavizumab Study Group2007Phase III trial of motavizumab (MEDI-524), an enhanced potency respiratory syncytial virus (RSV)-specific monoclonal antibody (Mab) for the prevention of serious RSV disease in high-risk infantsPediatric Academic Societies Annual MeetingToronto, Canada2007
   Google Scholar
• Chavez-BuenoSMejiasAWelliverRC2006Respiratory syncytial virus bronchiolitis: current and future strategies for treatment and prophylaxisTreat Respir Med54839417154675
   PubMedGoogle Scholar
• Chavez-BuenoSOlsenKDantonM2005Dynamics of respiratory syncytial virus (RSV) loads in hospitalized children45th Interscience Conference on Antimicrobial Agents and ChemotherapyWashington, DC2005
   Google Scholar
• CohenSAZanniRCohenA2008Palivizumab use in subjects with congenital heart disease: Results from the 2000–2004 Palivizumab Outcomes RegistryPediatr Cardiol29382717926087
   PubMed Web of Science ®Google Scholar
• CollinsPLCroweEJ2007Respiratory syncytial virus and metapneumovirusKnipeDMFields VirologyPhiladelphiaLippincott Williams and Wilkins160146
   Google Scholar
• DeVincenzoJPHallCBKimberlinDW2004Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutantsJ Infect Dis190975815295704
   PubMed Web of Science ®Google Scholar
• DevincenzoJP2004Natural infection of infants with respiratory syncytial virus subgroups A and B: a study of frequency, disease severity, and viral loadPediatr Res56914715470202
   PubMed Web of Science ®Google Scholar
• FearnsRCollinsPL1999Role of the M2-1 transcription antitermination protein of respiratory syncytial virus in sequential transcriptionJ Virol7358526410364337
   PubMed Web of Science ®Google Scholar
• FeltesTFCabalkaAKMeissnerHC2003Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart diseaseJ Pediatr1435324014571236
   PubMed Web of Science ®Google Scholar
• Fonseca-AtenMMichaelsGMCharsha-MayMM2007Respiratory syncytial virus (RSV) prophylaxis among pediatric solid organ transplant (SOT) programs4th Congress of the IPTA On Pediatric Transplantation 2007Cancun, Mexico
   Google Scholar
• GiebelsKMarcotteJEPodobaJ2008Prophylaxis against respiratory syncytial virus in young children with cystic fibrosisPediatr Pulmonol431697418085710
   PubMed Web of Science ®Google Scholar
• GlezenWPTaberLHFrankAL1986Risk of primary infection and reinfection with respiratory syncytial virusAm J Dis Child14054363706232
   PubMedGoogle Scholar
• GroothuisJRSimoesEALevinMJ1993Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study GroupN Engl J Med3291524308413475
   PubMed Web of Science ®Google Scholar
• HallCBDouglasRGJrGeimanJM1976Respiratory syncytial virus infections in infants: quantitation and duration of sheddingJ Pediatr89115180274
   PubMed Web of Science ®Google Scholar
• HallCB2000Respiratory Syncytial VirusMandellPrinciples and Practice of Infectious Diseases5 edChurchill Livingstone, Inc.
   Google Scholar
• HallWJHallCBSpeersDM1978Respiratory syncytial virus infection in adults: clinical, virologic, and serial pulmonary function studiesAnn Intern Med882035415653
   PubMed Web of Science ®Google Scholar
• JafriHSChavez-BuenoSMejiasA2004Respiratory syncytial virus induces pneumonia, cytokine response, airway obstruction, and chronic inflammatory infiltrates associated with long-term airway hyperresponsiveness in miceJ Infect Dis18918566515122522
   PubMed Web of Science ®Google Scholar
• JohnsonSOliverCPrinceGA1997Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virusJ Infect Dis1761215249359721
   PubMed Web of Science ®Google Scholar
• JohnsonTRVargaSMBracialeTJ2004Vbeta14(+) T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSVJ Virol7887536015280483
   PubMed Web of Science ®Google Scholar
• KuzikBAAl-QadhiSAKentS2007Nebulized hypertonic saline in the treatment of viral bronchiolitis in infantsJ Pediatr1512667070 e117719935
   PubMed Web of Science ®Google Scholar
• MalleyRDeVincenzoJRamiloO1998Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F proteinJ Infect Dis1781555619815203
   PubMed Web of Science ®Google Scholar
• MejiasAChavez-BuenoSRiosAM2004bAnti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV modelAntimicrob Agents Chemother4818112215105140
   PubMed Web of Science ®Google Scholar
• MejiasAChavez-BuenoSRiosAM2005bComparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potencyAntimicrob Agents Chemother494700716251314
   PubMed Web of Science ®Google Scholar
• MejiasAChavez-BuenoSSanchezP2005aRespiratory syncytial virus prophylaxisNeoReviewse6116
   Google Scholar
• MejíasARíosC-BSFonseca-AtenAM2004aComparative effect of an anti-respiratory syncytial virus monoclonal antibodies on viral replication and disease severity in the RSV murine model44th Interscience Conference on Antimicrobial Agents and Chemotherapy2004Washington DC, MD
   Google Scholar
• Palivizumab (Synagis®) package insert [online]Accessed Sept 1, 2005. URL: http://www.medimmune.com/pdf/products/synagis_pi.pdf
   Google Scholar
• Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infantsThe IMpact-RSV Study Group1998Pediatrics1025317
   PubMed Web of Science ®Google Scholar
• ParnesCGuillerminJHabersangR2003Palivizumab prophylaxis of respiratory syncytial virus disease in 2000–2001: results from The Palivizumab Outcomes RegistryPediatr Pulmonol35484912746948
   PubMed Web of Science ®Google Scholar
• PsarrasSPapadopoulosNGJohnstonSL2004Pathogenesis of respiratory syncytial virus bronchiolitis-related wheezingPaediatr Respir Rev5Suppl AS1798414980267
   PubMedGoogle Scholar
• [PREVENT] Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group1997Pediatrics999398989345
   PubMed Web of Science ®Google Scholar
• Red Book2006Report of the Committee on Infectious Diseases27th edElk Grove Village, ILAmerican Acedemy of Pediatrics
   Google Scholar
• Saez-LlorensXCastanoENullD1998Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study GroupPediatr Infect Dis J17787919779762
   PubMed Web of Science ®Google Scholar
• ShayDKHolmanRCNewmanRD1999Bronchiolitis-associated hospitalizations among US children, 1980–1996JAMA2821440610535434
   PubMed Web of Science ®Google Scholar
• SigursNGustafssonPMBjarnasonR2005Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13Am J Respir Crit Care Med1711374115516534
   PubMed Web of Science ®Google Scholar
• SimoesEAGroothuisJRCarbonell-EstranyX2007Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezingJ Pediatr1513442e117586188
   PubMed Web of Science ®Google Scholar
• SimoesEASondheimerHMTopFHJr1998Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study GroupJ Pediatr13349299787686
   PubMed Web of Science ®Google Scholar
• SpannKMTranKCChiB2004Suppression of the induction of alpha, beta, and lambda interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages [corrected]J Virol784363915047850
   PubMed Web of Science ®Google Scholar
• SteinRTSherrillDMorganWJ1999Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 yearsLancet354541510470697
   PubMed Web of Science ®Google Scholar
• WangEEProberCGMansonB1984Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosisN Engl J Med311165386504106
   PubMed Web of Science ®Google Scholar
• ZhaoXChenFPMegawAG2004bVariable resistance to palivizumab in cotton rats by respiratory syncytial virus mutantsJ Infect Dis1901941615529258
   PubMed Web of Science ®Google Scholar
• ZhaoXChenFPSullenderWM2004aRespiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton ratsVirology3186081214972528
   PubMed Web of Science ®Google Scholar